G. Catimel

发表

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

M. Piccart, J. Wanders, J. Verweij, 1994 .

SDZ PSC 833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors

G. Giaccone, S. Linn, H. Pinedo, 1994 .

Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.

S. Aamdal, J. Verweij, C. Sternberg, 1995, European journal of cancer.

Breast cancer: chemotherapy in the treatment of advanced disease.

G. Catimel, M. Clavel, 1993, European journal of cancer.

Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion

L. Dirix, R. Verdonk, C. Ardiet, 2004, Investigational new drugs.

Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors

Y. Merrouche, M. Alakl, J. Guastalla, 2004, Cancer Chemotherapy and Pharmacology.

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

J. Verweij, P. D. De Mulder, W. Oster, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors

C. Ardiet, G. Bastian, B. Tranchand, 1998, Cancer Chemotherapy and Pharmacology.

[Future trends in chemotherapy and impact on the management of emesis].

J. Droz, G. Catimel, 1995, Bulletin du cancer.

Head and Neck Cancer

G. Catimel, 2012, Drugs.

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck

M. Piccart, J. Wanders, J. Verweij, 1994 .

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.

J. Verweij, L. Dirix, D. Wagener, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin-induced hyponatremia and renal sodium wasting.

V. Cottin, C. Thieblemont, N. Barbet, 1995, Acta oncologica.

Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.

V. Diéras, M. Spielmann, P. Pouillart, 1996, Seminars in oncology.

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.

M. van Glabbeke, J. Verweij, A. V. van Oosterom, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Original article Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer

A. Graeff, J. Vermorken, W. Oster, 2005 .

Paclitaxel, Epirubicin and Cyclophosphamide Combination in First-Line Treatment of Metastatic Breast Cancer: A Dose Escalation Study

J. Bonneterre, M. Tubiana-Hulin, G. Catimel, 2004, Oncology.

345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)

J. Bergh, K. Gelmon, R. Paridaens, 1995 .

Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline‐ and/or paclitaxel‐containing regimens

J. Blay, P. Biron, I. Ray-Coquard, 1998, Cancer.

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

D. Khayat, T. Splinter, M. Fabbro, 2005, Supportive Care in Cancer.

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

K. Gelmon, M. Namer, J. Bonneterre, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.

L. Gras, J. Wanders, J. Verweij, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

A. Gouyette, G. Chabot, J. Guastalla, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

S. Culine, P. Hérait, J. Armand, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

A. te Velde, S. Aamdal, R. Paridaens, 1996, British Journal of Cancer.

An image cytometric DNA-analysis in breast neoplasms. Parameters of DNA-aneuploidy and their relationship with conventional prognostic factors.

C. Souchier, F. Chauvin, B. Fontanière, 1992, Pathology, research and practice.

A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.

G. Giaccone, S. Linn, H. Pinedo, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials.

I. Ray-Coquard, J. Droz, F. Chauvin, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1994 .

Phase I and pharmacokinetic study of a novel mitomycin C analog KW‐2149

L. Dirix, C. Ardiet, A. Oosterom, 1995, Anti-cancer drugs.

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

P. Hérait, J. Armand, M. Marty, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.

Y. Merrouche, P. Rebattu, J. Guastalla, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a.

T. Zénone, N. Barbet, G. Catimel, 1994, European journal of cancer.

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.

J. Armand, M. Marty, G. Catimel, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?

Y. Merrouche, G. Catimel, M. Clavel, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy.

P. Biron, F. Chauvin, P. Rebattu, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.

J. Bonneterre, V. Diéras, M. Spielmann, 1997, Seminars in oncology.

[Prognostic factors in the response of a first line chemotherapy in advanced breast cancer].

F. Chauvin, C. Lasset, J. Jacquin, 1990, Bulletin du cancer.

Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients

J. Armand, R. Bruno, M. Bayssas, 1996, Anti-cancer drugs.

Head and neck cancer: guidelines for chemotherapy.

G. Catimel, 1996, Drugs.

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

M. Piccart, J. Wanders, J. Verweij, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of taxotere in patients with advanced head and neck cancer

M. Piccart, J. Wanders, J. Verweij, 1993 .

Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1993 .

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

N. Le bail, G. Catimel, M. Clavel, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.